Screening programmes are among the medical imaging use cases where, at least for the majority, there is little urgency. As such, they were one of the first casualties of the cancellations in response to the developing Covid-19 pandemic in 2020, as providers sought to stem the spread of the virus. While the rationale for such action was sound, now, almost three years later the consequences are being keenly felt.

According to Bhvita Jani, Medical Imaging Research Manager and co-author of Signify Research’s Breast Imaging Report – 2022, these consequences are having a significant impact on the breast imaging market, although there are some technologies that are coming to the aid of providers looking to address the challenges.